PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval ...

Researchers at Dallas-based Colossal Biosciences rely on ancient DNA from extinct species and the genome of their closest living relatives to determine how they can be brought back. Why it matters: ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA ...

Nanosecond PFA Cardiac Surgical System for ablation of cardiac tissue to be highlighted in presentation and poster sessions. “We believe the Nanosecond PFA Cardiac Surgical System has the potential to ...

Pulse Biosciences (PLSE) highlights promising AFib catheter data and IDE-cleared pivotal trial progress—plus thyroid ...

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering ...

Pulse Biosciences (Nasdaq:PLSE) announced today that it enrolled the first patients in its NANOPULSE-AF study.

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.60, marking a +1.91% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.8% ...

View Lexaria Bioscience Corp. LEXX stock quote prices, financial information, real-time forecasts, and company news from CNN.